Afoxolaner - CAS 1093861-60-9
Catalog number: 1093861-60-9
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Afoxolaner is a potent isoxazoline insecticide and acaricide against Ixodes scapularis in dogs. It is indicated for the treatment and prevention of flea infestations, and the treatment and control of tick infestations in dogs and puppies. It is administered orally in meat-flavoured tablets, and poisons fleas once they start feeding. It is used either alone or as a combination treatment with milbemycin oxime.
Solid powder
10 mM in DMSO
-20°C Freezer
Afoxolaner is a potent isoxazoline insecticide and acaricide against Ixodes scapularis in dogs.
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
1.53±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
Canonical SMILES:
1.Comparative speed of kill of sarolaner (Simparica) and afoxolaner (NexGard) against induced infestations of Rhipicephalus sanguineus s.l. on dogs.
Six RH;Young DR;Holzmer SJ;Mahabir SP Parasit Vectors. 2016 Feb 19;9:91. doi: 10.1186/s13071-016-1375-y.
BACKGROUND: ;The brown dog tick, Rhipicephalus sanguineus sensu lato, commonly infests dogs globally, is the major vector of the pathogen that causes canine monocytic ehrlichiosis and also transmits Babesia vogeli. A rapid speed of kill of a parasiticide is essential to reduce the direct deleterious effects of tick infestation and the risk of tick-borne pathogen transmission. The speed of kill of a novel orally administered isoxazoline parasiticide, sarolaner (Simparica), against R. sanguineus sensu lato on dogs was evaluated and compared with afoxolaner (NexGard) for 5 weeks after a single oral dose.;METHODS: ;Based on pretreatment tick counts, 24 dogs were randomly allocated to oral treatment with either placebo, or label doses of sarolaner (2-4 mg/kg) or afoxolaner (2.5-6.8 mg/kg). Dogs were examined and live ticks counted at 8, 12, and 24 h after treatment and subsequent re-infestations on Days 7, 14, 21, 28, and 35. Efficacy was determined at each time point relative to counts for placebo dogs.;RESULTS: ;There were no adverse reactions to treatment. Based on geometric means, sarolaner provided >94 % efficacy within 8 h of treatment, and >99 % after 12 and 24 h. Against subsequent weekly re-infestations of ticks, sarolaner achieved ≥91.
2.Afoxolaner and fluralaner treatment do not impact on cutaneous Demodex populations of healthy dogs.
Zewe CM;Altet L;Lam ATH;Ferrer L Vet Dermatol. 2017 Oct;28(5):468-e107. doi: 10.1111/vde.12453. Epub 2017 May 23.
BACKGROUND: ;Fluralaner and afoxolaner are isoxazolines licensed for the treatment of flea and tick infestations. Isoxazolines have also shown efficacy for treatment of demodicosis. Nothing is known about the impact of these compounds on the populations of Demodex in healthy dogs.;HYPOTHESIS/OBJECTIVES: ;The objective of this study was to measure the prevalence of Demodex in the skin of healthy dogs prior to and following the use of either afoxolaner or fluralaner, using real-time PCR (RT-PCR) for Demodex DNA. Our hypothesis was that the use of an isoxazoline at the labelled dose would eliminate Demodex populations from the skin of healthy dogs.;ANIMALS AND METHODS: ;Twenty healthy dogs with no history of skin disease were recruited. Dogs were divided into two groups of ten, with each group receiving afoxolaner or fluralaner for the 90 day study period. Hairs were plucked from three body sites on Day 0 prior to medication administration, then again on days 30 and 90. RT-PCR amplifying Demodex DNA was performed on all samples.;RESULTS: ;At Day 0 (prior to treatment), five of the 20 dogs were positive for Demodex DNA at least in one skin site (25%). At Day 60, three of 18 dogs were positive (16.
3.Systemic insecticides used in dogs: potential candidates for phlebotomine vector control?
Gomez SA;Picado A Trop Med Int Health. 2017 Jun;22(6):755-764. doi: 10.1111/tmi.12870. Epub 2017 Apr 25.
Zoonotic visceral leishmaniasis (ZVL) is a public health problem endemic in some countries. Current control measures, in particular culling infected dogs, have not reduced ZVL incidence in humans. We evaluated the use of five systemic insecticides (spinosad, fluralaner, afoxolaner, sarolaner and moxidectin) currently used in dogs for other purposes (e.g. tick, flea control) in controlling ZVL transmission. The anti-phlebotomine capacity of these compounds confirmed in experimental studies makes their use in ZVL control programmes very promising. Limitations and benefits of using this new control tool are compared to current practices.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 256414-75-2 SEW 2871

SEW 2871
(CAS: 256414-75-2)

SEW 2871 is a potent, cell-permeable and selective sphingosine-1-phosphate type 1 receptor agonist (EC50= 13 nM). SEW 2871 suppresses the immune response by dec...

CAS 130405-40-2 (-)-Catechin gallate

(-)-Catechin gallate
(CAS: 130405-40-2)

(-)-catechin gallate, an antioxidant component existing in green tea, has been found to be probably effective in restraining tyrosine phosphorylation caused by ...

CAS 6310-41-4 NSC-41589

(CAS: 6310-41-4)

N-[2-(methylsulfanyl) phenyl]acetamide

CAS 2032282-97-4 Rbin-2

(CAS: 2032282-97-4)

Rbin-2 (ribozinoindole-2) is a potent and reversible inhibitor of Midasin (Mdn1), an enzyme belonging to the AAA+ (ATPases associated with diverse cellular acti...

CAS 73-78-9 Lidocaine hydrochloride

Lidocaine hydrochloride
(CAS: 73-78-9)

Lidocaine hydrochloride is the first amino amide–type local anesthetic and antiarrhythmic drug, which has anti-inflammatory properties in vitro and in vivo. It ...

Droxicainide hydrochloride
(CAS: 149572-05-4)

The hydrochloride salt form of Droxicainide, a piperidine derivative, has been found to be an potential antiarrhythmic agent.

CAS 1152314-49-2 BFF 122

BFF 122
(CAS: 1152314-49-2)

BFF 122 is a potent and selective inhibitor of kynurenine aminotransferase II (IC50 = 1 μM and >30 μM for KAT II and KAT I respectively).

CAS 217461-40-0 (±)-J 113397

(±)-J 113397
(CAS: 217461-40-0)

(+/-)-J 113397 has been found to be a NOP receptor antagonist and could restrain nociceptin/orphanin FQ-induced hyperalgesia in the mouse tail-flick test.

Quick Inquiry

Verification code

Featured Items